WithdrawnNot Applicable

Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study

Stopped: The study was placed on hold by the Sponsor for \~1 year. Given the prolonged hold and absence of participant activity, the study was closed.

United States0Started 2025-07-01

Plain-language summary

This study aims to evaluate whether the administration of vaginal estrogen along with Via, a hyaluronic acid-based vaginal moisturizer, offers superior relief from symptoms of genitourinary syndrome of menopause (GSM) in the urogynecologic patient population, compared to administration of vaginal estrogen alone.

Who can participate

Age range45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Postmenopausal (last menstrual period at least 12 months ago). * Aged 45 years or older and have symptoms of Genitourinary Syndrome of Menopause (GSM). * Have never tried vaginal estrogen therapy, or have tried vaginal estrogen therapy, but have not used vaginal estrogen and/or hyaluronic acid products for management of GSM symptoms within the last 3 months. * Capable of signing informed consent. * Capable and willing to follow all study-relation visits. Exclusion Criteria: * Subjects currently diagnosed with or undergoing treatment for hormone-sensitive disease (e.g. breast cancer) * Subjects currently using systemic hormone replacement therapy * Subjects currently using estrogen hormonal therapies or hormone modulators (aromatase inhibitors or selective estrogen receptor modulators)

What they're measuring

Percent change in vulvovaginal symptom questionnaire (VSQ) score

Timeframe: Baseline, Week 16

Trial details

NCT IDNCT07038070

SponsorNYU Langone Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-05-01

View on ClinicalTrials.gov More Genitourinary Syndrome of Menopause (GSM) trials